Senti Biosciences, Inc. reported its financial results for the fourth quarter and full year ended December 31, 2025, including a net loss of $14.5 million for Q4 2025 and $61.4 million for the full year. The company also provided updates on its clinical pipeline, including positive preliminary data for its lead program SENTI-202 in AML and the receipt of RMAT designation from the FDA.
Key takeaways
Reported Q4 2025 net loss of $14.5 million, or $0.53 per basic and diluted share.
Reported full year 2025 net loss of $61.4 million, or $2.73 per share.
Cash and cash equivalents were $16.4 million as of December 31, 2025.
Received Regenerative Medicine Advanced Therapy (RMAT) designation from the FDA for SENTI-202 for the treatment of adults with relapsed or refractory AML.
Reported updated positive preliminary clinical data from the ongoing Phase 1 trial of SENTI-202 in relapsed/refractory acute myeloid leukemia (AML).